| Literature DB >> 33036462 |
Saurav Panda1,2, Lora Mishra3, Heber Isac Arbildo-Vega4,5, Barbara Lapinska6, Monika Lukomska-Szymanska6, Shahnawaz Khijmatgar2,7, Abhishek Parolia8, Cristina Bucchi9, Massimo Del Fabbro2,10.
Abstract
The use of autologous platelet concentrates (APCs) in regenerative endodontic procedures is inconsistent and unclear. The aim of this meta-analysis was to evaluate the effectiveness of autologous platelet concentrates compared to traditional blood-clot regeneration for the management of young, immature, necrotic, permanent teeth. The digital databases MEDLINE, SCOPUS, CENTRAL, Web of Science, and EMBASE were searched to identify ten randomized clinical trials. The outcomes at postoperative follow-up, such as dentinal wall thickness (DWT), increase in root length (RL), calcific barrier formation (CB), apical closure (AC), vitality response (VR), and success rate (SR), were subjected to both qualitative synthesis and quantitative meta-analysis. The meta-analysis showed that APCs significantly improved apical closure (risk ratio (RR) = 1.17; 95% CI: 1.01, 1.37; p = 0.04) and response to vitality pulp tests (RR = 1.61; 95% CI: 1.03, 2.52; p = 0.04), whereas no significant effect was observed on root lengthening, dentin wall thickness, or success rate of immature, necrotic teeth treated with regenerative endodontics. APCs could be beneficial when treating young, immature, necrotic, permanent teeth regarding better apical closure and improved response to vitality tests.Entities:
Keywords: autologous platelet concentrate; immature teeth; meta-analysis; necrotic teeth; permanent teeth; review
Mesh:
Year: 2020 PMID: 33036462 PMCID: PMC7600252 DOI: 10.3390/cells9102241
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1PRISMA design flowchart showing the study selection process.
General Characteristics of the included studies.
| Author | Type of Study | Country | Groups of Study | Tooth | Etiology of Pulpal Necrosis | Follow-up Time in Months | |||
|---|---|---|---|---|---|---|---|---|---|
| ElSheshtawy et al. 2020 [ | RCT, Parallel | Egypt | 26 | 26 | A. PRP | 11 | Incisor | Secondary to trauma and dens invaginatus | 12 |
| B. BC | 11 | ||||||||
| Mittal et al. 2019 [ | RCT, Parallel | India | 16 | 16 | A. PRF | 4 | Incisor | Secondary to trauma/caries | 12 |
| B. BC | 4 | ||||||||
| Ragab et al. 2019 [ | RCT, Parallel | Egypt | 22 | 22 | A. PRF | 11 | Incisor | Secondary to trauma | 12 |
| B. BC | 11 | ||||||||
| Ulusoy et al. 2019 [ | RCT, Parallel | Turkey | 77 | 77 | A. PRP | 18 | Incisor | Secondary to trauma | Until complete healing 10–49 |
| B. PRF | 17 | ||||||||
| C. PP | 17 | ||||||||
| D. BC | 21 | ||||||||
| Rizk et al. 2019 [ | RCT, Parallel | Egypt | 26 | 26 | A. PRP | 13 | Incisor | Secondary to trauma | 12 |
| B. PRF | 12 | ||||||||
| Shivashankar et al. 2017 [ | RCT, Parallel | India | 60 | 60 | A. PRF | 20 | Incisor | Secondary to trauma/caries | 12 |
| B. BC | 15 | ||||||||
| C. PRP | 19 | ||||||||
| Alagl et al. 2017 [ | RCT, Split Mouth | Saudi Arabia | 16 | 32 | A. PRP | 15 | Incisor and premolars | Secondary to trauma/caries | 12 |
| B. BC | 15 | ||||||||
| Bezgin et al. 2015 [ | RCT, Parallel | Turkey | 20 | 22 | A. PRP | 11 | Incisor and premolars | Secondary to trauma/caries | 18 |
| B. BC | 11 | ||||||||
| Narang et al. 2015 [ | RCT, Parallel | India | 20 | 20 | A. MTA | 5 | NR | Secondary to trauma/caries | 18 |
| B. BC | 5 | ||||||||
| C. PRF | 5 | ||||||||
| D. PRP | 5 | ||||||||
| Jadhav et al. 2012 [ | RCT, Parallel | India | 20 | 20 | A. PRP | 10 | Incisor | Secondary to trauma/caries | 12 |
| B. BC | 10 |
Legend: RCT: randomized clinical trial; PRP: platelet-rich plasma; BC: induced blot clot; PRF: platelet-rich fibrin; PP: platelet pellet; MTA: mineral trioxide aggregate.
Details on the operative protocol of the included studies.
| Author | Presence of Periapical Lesion | Instrumentation | Irrigation Methods | Intra-Canal Medication | Recall Time (Weeks) | Preparation Protocol of APC | Access Restoration |
|---|---|---|---|---|---|---|---|
| ElSheshtawy et al. 2020 [ | Yes | No | 20 mL of 5.25% sodium hypochlorite. At recall, 20 mL of 2.5% sodium hypochlorite, followed by 20 mL sterile saline and 10 mL of 17% EDTA solution. | Triple Antibiotic Paste | NR | PRP was prepared according to Dohan et al. [ | MTA, using a layer of reinforced glass ionomer (Riva self-cure, SDI limited, Bayswater, Victoria, Australia) followed by resin composite (Filtek z250 universal restorative, 3 mol L 1ESPE, St. Paul, MN, USA). |
| Mittal et al. 2019 [ | Yes | Minimal (#30 K file) | 2.5% sodium hypochlorite (copious irrigation). | Double Antibiotic Paste | 4 weeks | PRF was prepared by drawing 5 mL of venous blood from the patient, collected in a dried glass test tube, and centrifuged at 2700 rpm for 12 min. | Glass ionomer cement followed by composite resin. |
| Ragab et al. 2019 [ | Yes | No | 20 mL of 5.25% sodium hypochlorite followed by 20 mL sterile saline. | Double Antibiotic Paste | 3 weeks | PRF was prepared by drawing 12 mL sample of whole blood intravenously from the patient’s right antecubital vein and centrifuged under 3000 rpm for 12 min. | MTA plus Light Cure Glass ionomer cement. |
| Ulusoy et al. 2019 [ | Yes | No | 20 mL 1.25% sodium hypochlorite. At recall, 2% chlorhexidine, saline and 1 mL 17% EDTA. | Triple Antibiotic Paste | 4 weeks | PRP: Citrated blood was centrifuged in a standard laboratory centrifuge PK 130 (ALC International; Cologno Monzese, Italy) for 15 min at 1250 revolutions per minute (rpm) to obtain PRP without erythrocytes and leukocytes. | MTA coronal barrier was sealed with a thin glass ionomer base, and final coronal restorations were placed at the same visit using acid etch composite resin. |
| Rizk et al. 2019 [ | Yes | No | 20 mL 2% sodium hypochlorite for 5 min, followed by 20 mL 17% EDTA. | Triple Antibiotic Paste | 3 weeks | PRP was prepared according to the description by Dohan et al. [ | An MTA orifice plug extending 2–3 mm in the canal was used to seal the canal orifice then glass ionomer (GC America, Alsip, IL) and composite (Z 250, 3 M ESPE) to give an effective and durable seal. |
| Shivashankar et al. 2017 [ | No | Minimal | 5.25% sodium hypochlorite (copious irrigation). | Triple Antibiotic Paste | 3 weeks | NR | NR |
| Alagl et al. 2017 [ | Yes | No | 2.5% sodium hypochlorite (20 mL), sterile saline (20 mL), and 0.12% chlorhexidine (10 mL), followed by 17% EDTA after 3 weeks. | Triple Antibiotic Paste | 3 weeks | PRP was prepared according to the description by Dohan et al. [ | NR |
| Bezgin et al. 2015 [ | Yes | No | 2.5% sodium hypochlorite (20 mL), sterile saline (20 mL), and 0.12% chlorhexidine (10 mL), followed by 5% EDTA (20 mL) after 3 weeks. | Triple Antibiotic Paste | 3 weeks | PRP was prepared according to the description by Dohan et al. [ | Final restoration was completed with white MTA (Angelus, Londrina, Brazil), reinforced glass ionomer cement (Ketac Molar Easymix; 3M ESPE, Seefeld, Germany), and composite resin (Filtek Supreme XT; 3M ESPE, St Paul, MN, USA). |
| Narang et al. 2015 [ | Yes | Minimal | 2.5% sodium hypochlorite (copious irrigation) | Triple Antibiotic Paste | 4 weeks | NR | Resin-modified glass ionomer cement was placed extending 3–4 mm in the canal. Access cavity was sealed with composite (Clearfil Majesty, Kuraray Medical Inc., Tokyo, Japan). |
| Jadhav et al. 2012 [ | No | Minimal (#60 H file) | 2.5% sodium hypochlorite (copious irrigation). | Triple Antibiotic Paste | NR | PRP: 8 mL of blood drawn by venipuncture of the antecubital vein was collected in a 10 mL sterile glass tube coated with an anticoagulant (acid citrate dextrose) and centrifuged at 2400 rpm for 10 min to separate PRP and platelet-poor plasma (PPP) from the red blood cell fraction. The top-most layer (PRP + PPP) was transferred to another tube and again centrifuged at 3600 rpm for 15 min to separate the PRP to precipitate at the bottom of the glass tube. This was mixed with 1 mL 10% calcium chloride to activate the platelets and to neutralize the acidity of acid citrate dextrose. | Resin-modified glass ionomer cement (Photac-Fill; 3M ESPE, St Paul, MN, USA) |
Legend: NR: not reported, EDTA: ethylene di-amine tetra-acetic acid, PRP: platelet-rich plasma, PRF: platelet-rich fibrin, CEJ: cementoenamel junction, MTA: mineral trioxide aggregate.
Risk of bias assessment of included trials.
| Author. | Year | Random Sequence Generation (Selection Bias) | Allocation Concealment (Selection Bias) | Blinding of Participants and Personnel (Performance Bias) | Blinding of Outcome Assessment (Detection Bias) | Incomplete Outcome Data (Attrition Bias) | Selective Reporting (Reporting Bias) | Overall Risk |
|---|---|---|---|---|---|---|---|---|
| ElSheshtawy et al. 2020 [ | 2020 | Low | Low | Low | Low | Low | Low | Low |
| Mittal et al. 2019 [ | 2019 | Low | Unclear | Low | Low | Low | Low | Moderate |
| Ragab et al. 2019 [ | 2019 | Low | Unclear | Unclear | Low | Unclear | Low | Moderate |
| Rizk et al. 2019 [ | 2019 | Low | Low | Unclear | Low | Low | Low | Moderate |
| ] Ulusoy et al. 2019 [ | 2019 | Low | Unclear | Unclear | Low | Low | Low | Moderate |
| Alagl et al. 2017 [ | 2017 | Low | Unclear | Unclear | Unclear | Low | Low | Moderate |
| Shivashankar et al. 2017 [ | 2017 | Low | Low | Low | Low | Low | Low | Low |
| Bezgin et al. 2015 [ | 2015 | Low | Unclear | Unclear | Unclear | Low | Low | Moderate |
| Narang et al. 2015 [ | 2015 | Low | Unclear | Unclear | Low | Low | Low | Moderate |
| Jadhav et al. 2012 [ | 2012 | Low | Unclear | Unclear | Unclear | Low | Low | Moderate |
Figure 2Forest plot showing a comparison of the dentinal wall thickness.
Figure 3Forest plot showing a comparison of the increase in root length (RL).
Figure 4Forest plot showing a comparison of apical closure (AC).
Figure 5Forest plot showing a comparison of the vitality response (VR).
Figure 6Forest plot showing a comparison of success rates (SR).